Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Hematologic Malignancy Clinical Trial

Official title:

A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03459170
• Other study ID #: BP-I-008
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 1, 2018
• Est. completion date: September 2035

Study information

• Verified date: July 2022
• Source: Bellicum Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.

Description:

Main Study:

Approximately 16 subjects will participate in the BPX-501 main study. The treatment consists of three courses of BPX-501 T cell infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0; DL2 on Days 30 and 60.

Two doses of rimiducid (AP1903) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion. A 0.1mg/kg initial dose of rimiducid which has demonstrated the ability to induce >50% BPX-501 T cell eradication in preclinical animal models will first be administered in the event of uncontrollable aGvHD. If there is no response to this dose within 24hrs + 12hrs a second dose of 0.4 mg/kg (which has been reported to induce T cell eradication of > 90%) will be administered. If there is no measurable GvHD response to the initial dose of 0.1 mg/kg rimiducid in 2 subjects, the starting dose of rimiducid will be 0.4 mg/kg for all subsequent subjects.

Rimiducid (AP1903) Optional PK Sub-Study:

Approximately 12 subjects will be recruited to participate in the optional Rimiducid (AP1903) PK sub-study. Subjects will be assigned to one of two arms and receive either 0.04mg/kg or 0.4mg/kg of Rimiducid (AP1903). Each arm will have a target enrollment of 6 subjects.

• Arm 1: 0.04mg/kg Rimiducid (AP1903), 6 subjects;

• Arm 2: 0.4mg/kg Rimiducid (AP1903), 6 subjects. Rimiducid PK samples and ECG data will be collected at Pre-dose (0 hour), 30 minutes, 2 hours and 8 hours following the initiation of rimiducid (AP1903) infusion.

Efforts shall be made to enroll at least one subject from each age subset into the PK sub-study: infants and toddlers (12 months to 23 months); children (2-11 years); and adolescents (12-18 years).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: September 2035
• Est. primary completion date: September 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

• Patients aged < 18

• Clinical diagnosis of one of the following pediatric hematological malignancies:

• High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]) in any CR

• Acute Leukemia that is minimal residual disease (MRD) positive at > 1copy per 1 x 10,000 reference copies pre-HSCT

• Myelodysplastic Syndrome (MDS)

• Hodgkin or Non-Hodgkin lymphomas

• Other high-risk hematological malignancy in CR eligible for stem cell transplantation per institutional standard

• Patients with a hematological malignancy who have received a prior allogeneic HSCT

• Patients with on-treatment relapse of AML within 6 months of initial CR

• Patients relapsing within 6 months of initial diagnosis of hematological malignancy.

• Planned or previous treatment of hematological malignancy with one of the following:

• Matched related HSCT

• Mismatched related HSCT

• For patients who have received a transplant, occurrence of one of the following > 30 days post-HSCT:

• Minimal residual disease (MRD) positive at > 1 copy per 1 x 10,000 reference copies post-HSCT

• Decreasing donor chimerism detected on two bone marrow biopsies or peripheral blood analyses at a > 7-day interval

• Recurrent disease

• Life expectancy >10 weeks;

• Signed donor and patient/guardian informed consent;

• For mismatched related donor recipients, a minimum genotypic identical match of 5/10 is required, as determined by high resolution typing, at least one allele of each of the following genetic loci must be matched: HLA-A, HLA-B, HLA-C, HLA- DRB1, and HLA-DQB1.

• Performance status: Karnofsky/Lansky score > 70%.

• Adequate organ function as measured by:

• High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]) in any CR

• High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]) in any CR

• Hepatic: direct bilirubin = 3x ULN, or AST/ALT = 5x ULN.

• Bone marrow;

• > 25% donor T cell chimerism

• ANC >1 x 10^9/L.

• Cardiac: LVEF at rest >45%.

• Pulmonary: FEV 1, FVC, DLCO (diffusion capacity for CO) > 50% predicted (corrected for hemoglobin); for children who are unable to perform pulmonary function tests due to age or developmental ability, there must be no evidence of dyspnea or no need for supplemental oxygen as evidenced by 02 saturation = 92% on room air.

• Hepatic: direct bilirubin = 3x ULN, or AST/ALT = 5x ULN.

• Renal: creatinine clearance = 2x of ULN for age

Exclusion Criteria:

= Grade II acute GVHD or moderate to severe chronic GVHD due to a previous allograft at the time of screening;

• Active CNS involvement by malignant cells (< 2 months prior to time of consent);

• Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).

• Positive HIV serology or viral RNA;

• Pregnancy (positive serum ßHCG test) or breast-feeding female;

• Patients of reproductive age unwilling to use effective forms of birth control or abstinence for a year after BPX-501 T cell infusion.

Related Conditions & MeSH terms

• Hematologic Malignancy
• Hematologic Neoplasms
• Neoplasms

Intervention

Biological:
• BPX-501 T cells
Biological: T cells transduced with CaspaCIDe® safety switch

Drug:
• rimiducid
administered to eliminate BPX-501 cells in the event of GVHD

Locations

Country	Name	City	State
Italy	San Matteo Hospital	Pavia
Italy	IRCCS Ospedale Pediatrico Bambino Gesù	Rome
Italy	Ospedale Infantile Regina Margherita	Turin

Sponsors (1)

Lead Sponsor	Collaborator
Bellicum Pharmaceuticals

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BPX-501 Safety	Incidence of treatment emergent adverse events of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in pediatric subjects with hematologic malignancies	Month 24
Primary	Mean plasma concentration	Measure plasma concentrations of rimiducid (AP1903) at two doses (Arm 1: 0.04mg/kg; Arm 2: 0.4mg/kg) in pediatric subjects, during and after a 2-hour infusion	pre-dose, 30 min, 2 hours and 8 hours after start of infusion
Secondary	Overall survival	Measure overall survival rates after BPX-501 infusion	Month 24
Secondary	Response Rate	Assess response rates after BPX-501 infusion	Month 24